Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krsnaa DiagnosticsNSE:KRSNAA +1.23%68 Return-on-Tangible-Equity is 17.11% as of Mar. 2026, which is 70% above its 10-year median of 10.07. GuruFocus rates NSE:KRSNAA with a GF Score™ of 68/100 and a GF Value™ of ₹911.15 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Krsnaa Diagnostics ranks better than 69.27% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Krsnaa Diagnostics's annualized net income for the quarter that ended in Mar. 2026 was ₹1,669 Mil. Krsnaa Diagnostics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹9,755 Mil. Therefore, Krsnaa Diagnostics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 17.11%.
The historical rank and industry rank for Krsnaa Diagnostics's Return-on-Tangible-Equity or its related term are showing as below:
NSE:KRSNAA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.37 Med: 10.07 Max: 1150.56
Current: 10.96
During the past 8 years, Krsnaa Diagnostics's highest Return-on-Tangible-Equity was 1,150.56%. The lowest was 7.37%. And the median was 10.07%.
NSE:KRSNAA's Return-on-Tangible-Equity is ranked better than 69.27% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs NSE:KRSNAA: 10.96
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Krsnaa Diagnostics Return-on-Tangible-Equity Related Terms
Krsnaa Diagnostics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Krsnaa Diagnostics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:KRSNAA vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Krsnaa Diagnostics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krsnaa Diagnostics Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Krsnaa Diagnostics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Krsnaa Diagnostics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.11% mean?
Krsnaa Diagnostics (NSE:KRSNAA) has a Return-on-Tangible-Equity of 17.11% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Krsnaa Diagnostics and its competitors. This is 70% above median its historical median of 10.07. Over the past decade, Krsnaa Diagnostics' Return-on-Tangible-Equity has ranged from 7.37 to 1,150.56. According to the industry distribution chart, Krsnaa Diagnostics ranks #59 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 30.7%.
Is Krsnaa Diagnostics' Return-on-Tangible-Equity too high?
Krsnaa Diagnostics' current Return-on-Tangible-Equity of 17.11% is 70% above median its 10-year median of 10.07. Over the past 10 years, this metric has ranged from a low of 7.37 to a high of 1,150.56. Based on the distribution chart, Krsnaa Diagnostics ranks #59 out of 192 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Krsnaa Diagnostics has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Krsnaa Diagnostics' Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Krsnaa Diagnostics ranks #59 out of 192 companies for Return-on-Tangible-Equity. This puts Krsnaa Diagnostics in the upper half of its industry. Historically, Krsnaa Diagnostics' own Return-on-Tangible-Equity has ranged from 7.37 to 1,150.56 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Krsnaa Diagnostics and its competitors. Krsnaa Diagnostics's current Return-on-Tangible-Equity is 17.11%, which is 70% above median its own 10-year median of 10.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krsnaa Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Krsnaa Diagnostics (NSE:KRSNAA) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹911.15, compared to a current price of ₹546.65 — trading 40% below its estimated fair value. The current Return-on-Tangible-Equity is 17.11%, which is 70% above median its 10-year median of 10.07. Krsnaa Diagnostics' overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Krsnaa Diagnostics (NSE:KRSNAA), the current Return-on-Tangible-Equity is 17.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krsnaa Diagnostics (NSE:KRSNAA) Overvalued in 2026?
Based on GuruFocus' analysis, Krsnaa Diagnostics stock appears to be undervalued.
The current stock price of ₹546.65 is trading 40% below its estimated GF Value™ of ₹911.15.
GuruFocus considers Krsnaa Diagnostics to be Significantly Undervalued.
Key valuation signals for NSE:KRSNAA:
Return-on-Tangible-Equity: 17.11% (70% above median its 10-year median of 10.07)
GF Value™: ₹911.15 vs. price of ₹546.65 (40% below fair value)
No single metric tells the full story. See the NSE:KRSNAA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krsnaa Diagnostics Ltd is a diagnostic services provider, both in Radiology and Pathology. It offers a wide range of diagnostic services such as imaging/radiology services, routine clinical laboratory tests, pathology, and tele-radiology services to private and public hospitals, medical colleges, and community health centres. The company's operations predominantly relate to providing Radiology and Pathology services for X Ray, CT Scan, MRI, Mammography, tele-reporting services, and all types of Blood and Urine investigations.
68GF Score
Get the complete analysis for NSE:KRSNAA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:KRSNAA has been successfully added to your 
